Pacira Pharmaceuticals buy Truist Financial Co.
Start price
25.07.25
/
50%
€18.90
Target price
25.07.26
€25.55
Performance (%)
14.29%
Price
30.12.25
€21.60
Summary
This prediction is currently active. The BUY prediction by Truist_Financial_Co_ currently has a performance of 14.29%. This prediction currently runs until 25.07.26. The prediction end date can be changed by Truist_Financial_Co_ at any time. Truist_Financial_Co_ has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Pacira Pharmaceuticals | 0.000% | 0.000% |
| iShares Core DAX® | 0.869% | 3.389% |
| iShares Nasdaq 100 | -0.852% | -2.157% |
| iShares Nikkei 225® | 0.436% | 1.060% |
| iShares S&P 500 | -0.122% | -0.270% |
Comments by Truist_Financial_Co_ for this prediction
In the thread Pacira Pharmaceuticals diskutieren
Pacira BioSciences, Inc. (NASDAQ: PCRX) was upgraded by analysts at Truist Financial Corporation from a "hold" rating to a "buy" rating. They now have a $30.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat
Stopped prediction by Truist_Financial_Co_ for Pacira Pharmaceuticals
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€19.10
07.11.25
07.11.25
€24.27
07.11.26
07.11.26
16.23%
30.12.25
30.12.25
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€18.40
25.07.24
25.07.24
€27.62
25.07.25
25.07.25
2.17%
26.07.25
26.07.25